Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma.

MLA

Weeden, Clare E., et al. “Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma.” Molecular Cancer Therapeutics, vol. 16, no. 8, Aug. 2017, pp. 1610–22. EBSCOhost, https://doi.org/10.1158/1535-7163.MCT-17-0174.

APA

Weeden, C. E., Holik, A. Z., Young, R. J., Ma, S. B., Garnier, J.-M., Fox, S. B., Antippa, P., Irving, L. B., Steinfort, D. P., Wright, G. M., Russell, P. A., Ritchie, M. E., Burns, C. J., Solomon, B., & Asselin-Labat, M.-L. (2017). Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 16(8), 1610–1622. https://doi.org/10.1158/1535-7163.MCT-17-0174

Chicago

Weeden, Clare E, Aliaksei Z Holik, Richard J Young, Stephen B Ma, Jean-Marc Garnier, Stephen B Fox, Phillip Antippa, et al. 2017. “Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma.” Molecular Cancer Therapeutics 16 (8): 1610–22. doi:10.1158/1535-7163.MCT-17-0174.